Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Neumora Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$211.19M. For fiscal 2025 it was -$240.95M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$240.95M | – |
| FY2024 | Dec 31, 2024 | -$262.83M | – |
| FY2023 | Dec 31, 2023 | -$251.43M | – |
| FY2022 | Dec 31, 2022 | -$135.28M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$52.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$58.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$57.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$70.78M | – |
| Q4 FY2024 | Dec 31, 2024 | -$62.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$76.49M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$113.84M | – |
| Q3 FY2023 | Sep 30, 2023 | -$56.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.57M | – |
See a number that looks wrong?